Ekso Bionics (NASDAQ:EKSO) CFO Purchases 1,308 Shares

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) CFO Jerome Wong bought 1,308 shares of Ekso Bionics stock in a transaction dated Monday, March 16th. The shares were purchased at an average cost of $11.85 per share, for a total transaction of $15,499.80. Following the completion of the transaction, the chief financial officer owned 4,184 shares of the company’s stock, valued at approximately $49,580.40. This represents a 45.48% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Ekso Bionics Stock Performance

EKSO traded up $0.14 during trading hours on Friday, reaching $10.54. 47,596 shares of the stock traded hands, compared to its average volume of 96,638. Ekso Bionics Holdings, Inc. has a fifty-two week low of $2.73 and a fifty-two week high of $13.50. The company has a debt-to-equity ratio of 0.09, a current ratio of 1.63 and a quick ratio of 1.07. The firm’s fifty day simple moving average is $9.95 and its two-hundred day simple moving average is $6.79.

Analyst Ratings Changes

EKSO has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ekso Bionics in a research report on Monday, December 22nd. Wall Street Zen upgraded Ekso Bionics to a “hold” rating in a research note on Saturday, December 13th. Finally, HC Wainwright downgraded Ekso Bionics from a “buy” rating to a “neutral” rating in a report on Wednesday, December 31st. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $6.00.

Institutional Investors Weigh In On Ekso Bionics

A number of institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in Ekso Bionics in the third quarter worth about $57,000. Shay Capital LLC acquired a new position in shares of Ekso Bionics in the 3rd quarter valued at about $67,000. Citadel Advisors LLC acquired a new position in shares of Ekso Bionics in the 3rd quarter valued at about $198,000. Geode Capital Management LLC grew its position in shares of Ekso Bionics by 68.9% during the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after buying an additional 10,281 shares during the last quarter. Finally, Consolidated Portfolio Review Corp acquired a new stake in Ekso Bionics during the third quarter worth about $333,000. Institutional investors and hedge funds own 6.42% of the company’s stock.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.